Floatz logo

Olvi-Vec

Ovarian Cancer

Genelux CorporationPhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
59/ 100

Competitive context

525 Active assets in the Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Carboplatin
Fudan University
Phase 4BB
Irinotecan
ARCAGY/ GINECO GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

Olvi-Vec is also rated in:

peritoneal carcinomatosisDormant
CCC
Indicative ·
48 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →